Related Experiment Video
Updated: Feb 18, 2026
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Immunohistochemical study of cyclin A and p16 expression in patients with renal cell carcinoma
Dragana Latic1, Sanja Radojevic-Skodric, Srdjan Nikolic
1The Institute of Pathology, School of Medicine, University of Belgrade, Belgrade, Serbia.
Purpose:
Renal cell carcinoma (RCC) is the most common malignant kidney tumor in adults. Dysregulation of the cell cycle can lead to cancer development. In this study, the mitosis-associated cyclin A and p16, a negative controller, were investigated as potential key points in the RCC development.
Methods:
This retrospective study included 74 patients with RCC. The expression of cyclin A and p16 and their correlation to histopathological parameters (TNM stage, histological subtype, nuclear grade, tumor size), gender, age, and clinical outcome were studied and analyzed.
Results:
The highest median value for cyclin A (40%; range 0-70)) and for p16 (57.5%); range 35-80) were found in the papillary histological subtype. Survival analysis showed that in the group of patients that had died before September 2015, the median value for cyclin A was 20% (range 0-60), which was significantly higher than 5% (range 0-70), found in the group of patients that survived (p=0.019).
Conclusions:
In relation to the histological subtype, the papillary type of RCC was associated with a significantly higher expression of cyclin A and p16 compared to other subtypes of RCC. High expression of cyclin A indicated worse prognosis, therefore cyclin A could be considered to be a significant prognostic marker.
Insights
High expression of cyclin A in renal cell carcinoma (RCC) is linked to poorer patient prognosis, particularly in papillary RCC subtypes. This suggests cyclin A is a significant prognostic marker for kidney cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Renal cell carcinoma (RCC) is the predominant adult kidney malignancy.
- Cell cycle dysregulation is a known driver of cancer development.
- Investigating cell cycle regulators like cyclin A and p16 offers insights into RCC pathogenesis.
Purpose of the Study:
- To investigate the expression of cyclin A and p16 in renal cell carcinoma.
- To determine the correlation between cyclin A and p16 expression and RCC histopathological parameters and clinical outcomes.
- To evaluate the potential of cyclin A and p16 as prognostic markers in RCC.
Main Methods:
- Retrospective analysis of 74 RCC patient cases.
- Assessment of cyclin A and p16 expression.
- Correlation analysis with TNM stage, histological subtype, nuclear grade, tumor size, gender, age, and clinical outcome.
Main Results:
- Papillary RCC subtype showed the highest median expression of both cyclin A (40%) and p16 (57.5%).
- Patients who died before September 2015 had significantly higher median cyclin A expression (20%) compared to survivors (5%).
- Higher cyclin A and p16 expression was significantly associated with the papillary histological subtype.
Conclusions:
- Papillary RCC exhibits significantly higher cyclin A and p16 expression compared to other subtypes.
- Elevated cyclin A expression is indicative of a worse prognosis in RCC patients.
- Cyclin A emerges as a potentially significant prognostic marker for renal cell carcinoma.
More Related Videos
Related Concept Videos
02:34Inhibition of Cdk Activity
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...